-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $90

Benzinga·07/30/2026 18:42:30
Listen to the news
Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $75 to $90.